Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response

A. Rody*, T. Karn, R. Gätje, A. Ahr, C. Solbach, K. Kourtis, M. Munnes, S. Loibl, S. Kissler, E. Ruckhäberle, U. Holtrich, G. v. Minckwitz, M. Kaufmann

*Korrespondierende/r Autor/-in für diese Arbeit
60 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medizin & Biologie